ATLANTA, Feb. 25 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC
Bulletin Board: GOVX), http://www.geovax.com, an Atlanta based biotechnology
company, announced their HIV/AIDS vaccine is one of the select few to move
forward into Phase 2a human trials by the HIV Vaccine Trials Network
(HVTN), a network supported by the National Institutes of Health (NIH).

GeoVax's AIDS vaccine is believed to be only the fifth [5th] HIV/AIDS
vaccine to be selected to move forward into Phase 2a human trials conducted
by the HVTN. In contrast, it was approximately HVTN's 65th vaccine
evaluated in Phase 1 human trials.

Attended by over 20 HVTN personnel and key GeoVax personnel, this event
included individuals instrumental in organizing and implementing human
clinical trials designed to evaluate the GeoVax HIV/AIDS vaccine. The newly
planned Phase 2 trials are tentatively scheduled to start mid-2008 and will
involve up to 500 participants at several locations in the USA.

"We are delighted that our HIV/AIDS vaccine has been selected to move
forward into Phase 2 trials. Our vaccine continues to demonstrate the
promise of not only being safe but also effective at eliciting potentially
protective immune responses," stated Dr Harriet Robinson, Senior Vice
President, Research & Development at GeoVax.

"GeoVax is extremely pleased to have passed the significant hurdles
required to move into Phase 2 trials. Only a handful of AIDS vaccines have
reached the Phase 2 level of clinical evaluation with the HVTN, including
the previously failed vaccines of Vaxgen and Merck," stated GeoVax
President, Don Hildebrand.

GeoVax has completed two Phase 1 human trials evaluating its AIDS
vaccines with excellent results and has three additional human trials
currently underway. Due to promising results from these five trials the
HVTN is pushing forward with plans for critically important and larger
Phase 2 human trials.

GeoVax AIDS vaccine technology and composition are significantly
different than the Merck & Co. Inc. AIDS vaccines that recently had their
human trials halted due to safety and effectiveness concerns.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop,
manufacture, license and commercialize human vaccines for diseases caused
by HIV-1 (Human Immunodeficiency Virus) and other infectious agents.
GeoVax's AIDS vaccine technology is covered by 20 issued or filed patent
applications. GeoVax HIV/AIDS vaccines are designed to prevent Acquired
Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1 and may
be effective as therapeutics (treatment of people already infected with
AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected
individuals are in the planning stage.

GeoVax's core HIV/AIDS vaccine technologies were developed through a
collaboration of colleagues at Emory University's Vaccine Center, the
National Institutes of Health (NIH), Centers for Disease Control and
Prevention (CDC) and the GeoVax team.

GeoVax HIV/AIDS vaccines have moved forward in human clinical trials
conducted by the HIV Vaccine Trials Network (HVTN] based in Seattle,
Washington. The HVTN, funded and supported by the National Institutes of
Health [NIH), is the largest worldwide clinical trials program dedicated to
the development and testing of HIV/AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by the
National Institute of Allergy and Infectious Diseases (NIAID). The NIH
provided additional support to GeoVax AIDS vaccine development program with
a $15 million IPCAVD grant awarded in late 2007.

-- Are planned for mid 2008 Phase 2 trials based on success in previous

HVTN conducted trials

Safe Harbor Statement: All statements in this news release, not
statements of historical fact, are forward-looking statements. These
statements are based on expectations and assumptions on the date of this
press release and are subject to numerous risks and uncertainties which
could cause actual results to differ materially from those described in
forward-looking statements. Risks and uncertainties include, but are not
limited to, whether: GeoVax can develop and manufacture these vaccines with
the desired characteristics in a timely manner, GeoVax's vaccines will be
safe for human use, GeoVax's vaccines will effectively prevent AIDS in
humans, vaccines will receive regulatory approvals necessary to be licensed
and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may be more
effective or easier to use than GeoVax's products, and other factors over
which GeoVax has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. Certain matters
discussed in this news release are forward-looking statements involving
certain risks and uncertainties including, without limitations, risks
detailed in the Company's Securities and Exchange Commission filings and
report.

(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...

(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...

(Date:12/8/2016)... -- Research and Markets has announced the addition of the ... ... report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. The report ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period 2015 through 2022. Also, ...

(Date:12/7/2016)... PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... trials with the announcement that it is one of the early adopters completing EU-U.S. ... Shield Framework is designed to provide companies on both sides of the Atlantic with ...

(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...